The science of slowed gastrointestinal motility GLP-1 receptor agonists act on the gutbrain axis and are known to slow gastric emptying and overall gastrointestinal transit , contributing to early satiety and appetite suppression. As intestinal transit slows, the colon has more time to absorb water from stool , leading to hard, dry stools that are difficult to pass . Constipation is a common, dose-related adverse effect listed in FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) and is most frequently reported during dose escalation , with improvement over time., Step-by-Step MD Protocol for Relief 1
As such, GLP-1 signaling has become a major therapeutic strategy for metabolic disorders
In April, a paper in BMC Ophthalmology identified patterns of eye problems among people who took oral or injectable semaglutide
Special situations and additional considerations Medicare and Medicaid Anthem plans Medicare Part D currently does not cover GLP-1 medications for weight loss
Refrigeration slows down any breakdown of semaglutide (the active ingredient in Ozempic), making sure your medication stays potent until you need it
:max_bytes(150000):strip_icc()/WhatstheDifferenceBetweenOzempicWegovyandMounjaro-illo-a8f5a23fe4914586b4488472fe15f112.png)
